ALLMedicine™ Exfoliative Dermatitis Center
Research & Reviews 43 results
https://doi.org/10.1007/s00403-022-02463-8
Archives of Dermatological Research; Kim YH, Bhandarkar AR et. al.
Nov 12th, 2022 - Erythroderma is an uncommon but serious dermatologic disorder that often requires hospitalization for diagnosis and treatment. However, little is known about predictors influencing cost and patient outcomes. The present study sought to characteriz...
http://emedicine.medscape.com/article/1053325-overview
Mar 15th, 2022 - Practice Essentials Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo t...
https://emedicine.medscape.com/article/1053325-overview
Mar 15th, 2022 - Practice Essentials Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo t...
https://emedicine.medscape.com/article/1053325-print
Mar 15th, 2022 - Practice Essentials Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo t...
https://emedicine.medscape.com/article/762236-overview
Jun 22nd, 2021 - Practice Essentials Exfoliative dermatitis is characterized by generalized erythema with scaling or desquamation affecting at least 90% of the body surface area. Systemic derangements may occur with exfoliative dermatitis, including peripheral ede...
Drugs 530 results see all →
Clinicaltrials.gov 2 results
https://clinicaltrials.gov/ct2/show/NCT02271724
May 16th, 2016 - Chronic inflammatory peripheral neuropathies are characterized by progressive deterioration in muscle strength, loss of sensibility, diminished or absent reflexes and impaired fine motor control. Often it is caused by demyelination which is suitab...
https://clinicaltrials.gov/ct2/show/NCT00748319
Aug 22nd, 2012 - Background : The most frequent cutaneous T-cell lymphomas (CTCL) are mycosis fungoid and Sezary syndrome. Both are due to the proliferation of a CD4+ T-cell clone in the skin, associated with a blood involvement in Sezary syndrome. Mycosis fungoid...
News 10 results
https://www.onclive.com/view/fda-approves-bevacizumab-adcd-biosimilar-in-six-solid-tumors
Sep 28th, 2022 - The FDA has approved bevacizumab-adcd (Vegzelma), a bevacizumab (Avastin) biosimilar, for the treatment of six types of cancer: metastatic colorectal cancer; recurrent or metastatic nonsquamous non–small cell lung cancer (NSCLC); recurrent gliobla...
https://www.onclive.com/view/fda-approves-third-bevacizumab-biosimilar
Apr 25th, 2022 - The FDA has approved bevacizumab-maly (Almysys), a biosimilar of bevacizumab (Avastin). This regulatory decision represents the third bevacizumab biosimilar to receive the green light in the United States.1,2 The biosimilar was developed by the g...
https://www.onclive.com/view/survival-not-improved-by-adjuvant-bevacizumab-in-nsclc
Dec 20th, 2020 - Heather A. Wakelee, MD The addition of bevacizumab (Avastin) to adjuvant chemotherapy did not improve overall survival (OS) in patients with surgically resected early-stage non—small cell lung cancer (NSCLC), according to results of the phase III...
https://www.onclive.com/view/eu-approves-midostaurin-for-aml-advanced-systemic-mastocytosis
Nov 13th, 2020 - Bruno Strigini, CEO The European Commission has approved midostaurin (Rydapt) for adults with newly diagnosed FLT3-positive acute myeloid leukemia (AML) and advanced systemic mastocytosis (SM), including aggressive systemic mastocytosis (SM), SM ...
https://www.mdedge.com/hematology-oncology/article/203812/gynecologic-cancer/fda-approves-bevacizumab-bvzr-several-cancers
Laura Nikolaides
Jun 28th, 2019 - The Food and Drug Administration has approved bevacizumab-bvzr (Zirabev) – a biosimilar to bevacizumab (Avastin) – for the treatment of five cancers: metastatic colorectal cancer (mCRC); unresectable, locally advanced, recurrent or metastatic non-.